STORM to Use Evotecs Integrated Ind-Enabling Platform, Indigo
Category : #Health  By- Madhura Dethe  Date: 2020-11-18
  • share
  • Twitter
  • Facebook
  • LinkedIn
STORM to Use Evotecs Integrated Ind-Enabling Platform, Indigo

Evotec SE announced that as a part of its ongoing partnership with STORM Therapeutics, the latter has selected STC-15 as a superior development candidate. It will use the unique integrated, enhanced IND-enabling platform of Evotec, INDiGO to develop STC-15 to an IND application in 2021.

STORM found STC-15, which is a small molecule, orally bioavailable inhibitor of the enzyme METTL3 that targets modulation of RNA epigenetics, a completely novel mechanism of action, to treat acute myeloid leukaemia (AML) and other haematological and solid cancers with the help from pre-clinical drug identification engine of Evotec.

STORM is a leader in the worldwide field of RNA modulation having verified in vivo proof of idea activity of the 1st methyltransferase inhibitor in applicable models for myeloid and solid tumors. METTL3 is one of two programs from the STORM platform that are already demonstrated in vivo activity.

Evotec’s Chief Operating Officer, Dr. Craig Johnstone stated that the relation with STORM signifies the ability of Evotec to support the investigation of new and exciting biology to make the most of innovation along with executing efficiently with the fast and continuous integration from the target through to IND.

The CEO at STORM, Dr. Keith Blundy, affirmed that the identification of STC-15 was done with Evotec’s support and is a very strong and selective METTL3 inhibitor that is efficacious in leukaemia cells refractory to chemotherapy treatment. These patients will be combined in the primary clinical trials that aim to speed-up clinical evidence of concept for patients with limited other options along with discovering combinations with the standard of care.

STORM aims to be the first company in the world to provide a disease-modifying agent that operates by targeting RNA-modulating enzymes. With help from Evotec, the company has quickly and successfully progressed the work that results in a superior development candidate, confirmed Dr. Blundy.

 

Source: https://www.biospace.com/article/releases/evotec-and-storm-therapeutics-leverage-indigo-platform-to-progress-oncology-project-towards-clinical-studies/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Madhura Dethe    

Madhura Dethe

Having pursued a post graduate degree in English Literature, Madhura’s interest naturally drifted toward writing. Presently, she works as an associate content writer for lunchwithapunch.com and pens down insightful articles on healthcare, technology, and business tr...

Read More

Most Read

Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists
Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists
By- Puja More  Date: 2020-12-03

Biohaven Pharmaceutical Holding Company and Sosei Group Corporation have signed a collaboration and licensing agreement under which the form...

Cerus receives FDA nod for INTERCEPT Blood System for Cryoprecipitation
Cerus receives FDA nod for INTERCEPT Blood System for Cryoprecipitation
By- Madhura Dethe  Date: 2020-12-02

Adding to yet other initiatives and accomplishments in the medical fraternity, a California-based pathogen-protected blood component develop...

Nigeria set to commence installation of 5Mn solar home power systems
Nigeria set to commence installation of 5Mn solar home power systems
By- Puja More  Date: 2020-12-01

The first phase of installation is expected to be commenced in December 2020 nationwide. The Federal Government of Nigeria has recently sta...

Ascentage partners with U-M to attain license for a MDM2 degrader
Ascentage partners with U-M to attain license for a MDM2 degrader
By- Puja More  Date: 2020-11-30

Acquisitions, collaborations, and mergers have become a common practice in the medical and biotechnology sector in recent years. Speaking of...

Our Conrtributor

Prince Charles urges companies to join Terra Carta, the Earth charter

Prince Charles urges companies to join Terra Carta, the Earth charter

By- Madhura Dethe

The Prince of Wales is urging companies to invest in a more sustainable future and contribute more t...

Samsung working on 600 MP camera sensor, can zoom in 4k and 8K videos

Samsung working on 600 MP camera sensor, can zoom in 4k and 8K videos

By- Madhura Dethe

In February 2020, the South Korean multinational conglomerate company- Samsung had launched the 108M...

India expected to emerge as the largest COVID-19 vaccine buyer

India expected to emerge as the largest COVID-19 vaccine buyer

By- Madhura Dethe

With more than 40,000 COVID-19 cases being diagnosed daily in the country, India is all set to emerg...